The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
Abstract
In most patients with multiple sclerosis, the disease initiates with a first attack or clinically isolated syndrome. At this phase, magnetic resonance imaging is an important predictor of conversion to multiple sclerosis. With the exception of oligoclonal bands, the role of other biomarkers in patients with clinically isolated syndrome is controversial. In the present study, we aimed to identify proteins associated with conversion to multiple sclerosis in patients with clinically isolated syndrome. We applied a mass spectrometry-based proteomic approach (isobaric labelling) to previously collected pooled cerebrospinal fluid samples from patients with clinically isolated syndrome, who subsequently converted to clinically definite multiple sclerosis (n=30) and patients who remained as having clinically isolated syndrome (n=30). Next, three of the most represented differentially expressed proteins, i.e. ceruloplasmin, vitamin D-binding protein and chitinase 3-like 1 were selected for validation in individual cerebrospinal fluid samples by enzyme-linked immunosorbent assay. Only chitinase 3-like 1 was validated and cerebrospinal fluid levels were increased in patients who converted to clinically definite multiple sclerosis compared with patients who continued as clinically isolated syndrome (P=0.00002) and controls (P=0.012). High cerebrospinal fluid levels of chitinase 3-like 1 significantly correlated with the number of gadolinium enhancing lesions and the number of T2 lesions observed in brain magnetic resonance imaging scans performed at baseline, and were associated with disability progression during follow-up and shorter time to clinically definite multiple sclerosis (log-rank P-value=0.003). Cerebrospinal fluid chitinase 3-like 1 levels were also measured in a second validation clinically isolated syndrome cohort and found to be increased in patients who converted to multiple sclerosis compared with patients who remained as having clinically isolated syndrome (P=0.018). Our results indicate that patients who will convert to clinically definite multiple sclerosis could be distinguished from those patients who will remain as clinically isolated syndrome by proteomic analysis of cerebrospinal fluid samples. Although protein levels are also increased in other disorders characterized by chronic inflammation, chitinase 3-like 1 may serve as a prognostic biomarker for conversion to multiple sclerosis and development of disability which may help to improve the understanding of the aetiopathogenesis in the early stages of multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Barkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research
Wiese, S., Reidegeld, K. A., Meyer, H. E., & Warscheid, B. (2007) · PROTEOMICS · doi:10.1002/pmic.200600422 · Cited by 800
Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 616
Wu, W. W., Wang, G., Baek, S. J., & Shen, R.-F. (2006) · Journal of Proteome Research · doi:10.1021/pr050405o · Cited by 576
Semaphorin 7A promotes axon outgrowth through integrins and MAPKs
Jeroen Pasterkamp, R., Peschon, J. J., Spriggs, M. K., & Kolodkin, A. L. (2003) · Nature · doi:10.1038/nature01790 · Cited by 515
A perspective on the use of iTRAQTM reagent technology for protein complex and profiling studies
Zieske, L. R. (2006) · Journal of Experimental Botany · doi:10.1093/jxb/erj168 · Cited by 468
Renkema, G. H., Boot, R. G., Au, F. L., Donker‐Koopman, W. E., Strijland, A., Muijsers, A. O., Hrebicek, M., & Aerts, J. M. F. G. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2510504.x · Cited by 402
DeSouza, L., Diehl, G., Rodrigues, M. J., Guo, J., Romaschin, A. D., Colgan, T. J., & Siu, K. W. M. (2005) · Journal of Proteome Research · doi:10.1021/pr049821j · Cited by 362
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Tintoré, M., Rovira, A., Río, J., Tur, C., Pelayo, R., Nos, C., Téllez, N., Perkal, H., Comabella, M., Sastre-Garriga, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000280576.73609.c6 · Cited by 345
Self-citationBaseline MRI predicts future attacks and disability in clinically isolated syndromes
Tintoré, M., Rovira, A., Río, J., Nos, C., Grivé, E., Téllez, N., Pelayo, R., Comabella, M., Sastre-Garriga, J., & Montalban, X. (2006) · Neurology · doi:10.1212/01.wnl.0000237354.10144.ec · Cited by 282
Self-citationLack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M. S., Hartung, H.-P., Polman, C. H., Miller, D. H., Montalban, X., Barkhof, F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063602 · Cited by 255
Self-citationJensen, B. V., Johansen, J. S., & Price, P. A. (2003) · PubMed · Cited by 209
Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity
Johansen, J. (1999) · Rheumatology · doi:10.1093/rheumatology/38.7.618 · Cited by 184
Inflammatory Cytokines Induce Production of CHI3L1 by Articular Chondrocytes
Recklies, A. D., Ling, H., White, C., & Bernier, S. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510146200 · Cited by 164
Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients
Dumont, D., Noben, J., Raus, J., Stinissen, P., & Robben, J. (2004) · PROTEOMICS · doi:10.1002/pmic.200300715 · Cited by 147
High serum YKL-40 level in patients with small cell lung cancer is related to early death
Johansen, J. S. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.05.010 · Cited by 133
Milner, R., Crocker, S. J., Hung, S. Y., Wang, X., Frausto, R. F., & del Zoppo, G. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.8158 · Cited by 132
The impact of blood contamination on the proteome of cerebrospinal fluid
You, J., Gelfanova, V., Knierman, M. D., Witzmann, F. A., Wang, M., & Hale, J. E. (2004) · PROTEOMICS · doi:10.1002/pmic.200400889 · Cited by 123
Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors
Gveric, D. O., Herrera, B., Petzold, A., Lawrence, D. A., & Cuzner, M. L. (2003) · Brain · doi:10.1093/brain/awg167 · Cited by 118
Vos, K., Steenbakkers, P. G. A., Miltenburg, A., Bos, E. S., van den Heuvel, M. W., van Hogezand, R. A., Vries, D. R., Breedveld, F. C., & Boots, A. M. H. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.7.544 · Cited by 115
Precise protein quantification based on peptide quantification using iTRAQ™
Boehm, A., Pütz, S. M., Altenhöfer, D., Sickmann, A., & Falk, M. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-214 · Cited by 111
Johansen, J. S., Milman, N. T., Hansen, M. S., Garbarsch, C., Price, P. A., & Graudal, N. A. (2004) · Respiratory Medicine · doi:10.1016/j.rmed.2004.09.016 · Cited by 99
Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis
Irani, D. N., Anderson, C., Gundry, R. L., Cotter, R. J., Moore, S., Kerr, D. A., McArthur, J. C., Sacktor, N., Pardo, C. A., Jones, M., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20786 · Cited by 98
van Bilsen, J. H. M., van Dongen, H., Lard, L. R., van der Voort, E. I. H., Elferink, D. G., Bakker, A. M., Miltenburg, A. M. M., Huizinga, T. W. J., de Vries, R. R. P., & Toes, R. E. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407704101 · Cited by 80
Cerebrospinal fluid proteome profile in multiple sclerosis
Lehmensiek, V., Süssmuth, S., Tauscher, G., Brettschneider, J., Felk, S., Gillardon, F., & Tumani, H. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507076406 · Cited by 77
Noben, J., Dumont, D., Kwaśnikowska, N., Verhaert, P. D. E. M., Somers, V. A., Hupperts, R., Stinissen, P., & Robben, J. (2006) · Journal of Proteome Research · doi:10.1021/pr0504788 · Cited by 76
Multiple sclerosis‐related proteins identified in cerebrospinal fluid by advanced mass spectrometry
Stoop, M. P., Dekker, L. J. M., Titulaer, M. K., Burgers, P. C., Smitt, P. A. E. S., Luider, T. M., & Hintzen, R. Q. (2008) · PROTEOMICS · doi:10.1002/pmic.200700446 · Cited by 74
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
Diefenbach, C., Shah, Z., Iasonos, A. E., Barakat, R. R., Levine, D. A., Aghajanian, C. A., Sabbatini, P. J., Hensley, M. L., Konner, J. A., Tew, W. P., et al. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.028 · Cited by 64
Kappa Free Light Chains in Cerebrospinal Fluid as Markers of Intrathecal Immunoglobulin Synthesis
Fischer, C., Arneth, B. M., Koehler, J., Lotz, J., & Lackner, K. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.033977 · Cited by 63
Tumani, H., Lehmensiek, V., Rau, D., Guttmann, I., Tauscher, G., Mogel, H., Palm, C., Hirt, V., Suessmuth, S. D., Sapunova-Meier, I., et al. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.057 · Cited by 62
Kücür, M., İşman, F. K., Balcı, M. B. C., Önal, B., Hacıbekiroğlu, M., Özkan, F., & Özkan, A. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.07.020 · Cited by 60
Antimyelin Antibodies with No Progression to Multiple Sclerosis
Pelayo, R., Tintoré, M., Montalbán, X., Rovira, À., Espejo, C., Reindl, M., & Berger, T. (2007) · New England Journal of Medicine · doi:10.1056/nejmc062467 · Cited by 57
Self-citationErzin, Y. Z., Uzun, H., Karataş, A., & Çelık, A. F. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05121.x · Cited by 56
Serum YKL-40 as a marker for cervical adenocarcinoma
Mitsuhashi, A., Matsui, H., Usui, H., Nagai, Y., Tate, S., Unno, Y., Hirashiki, K., Seki, K., & Shozu, M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn552 · Cited by 56
Alteration of DBP Levels in CSF of Patients with MS by Proteomics Analysis
Qin, Z., Qin, Y., & Liu, S. (2008) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-008-9312-z · Cited by 53
No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS
Niino, M., Kikuchi, S., Fukazawa, T., Yabe, I., & Tashiro, K. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00099-1 · Cited by 52
Serum carnosinase activities in central nervous system disorders
Wassif, W., Sherwood, R. A., Amir, A., Idowu, B. D., Summers, B. A., Leigh, N. P., & Peters, T. J. (1994) · Clinica Chimica Acta · doi:10.1016/0009-8981(94)90027-2 · Cited by 47
Plasma chitotriosidase activity in multiple sclerosis
Comabella, M., Domínguez, C., Rio, J., Martín-Gallán, P., Vilches, A., Vilarrasa, N., Espejo, C., & Montalban, X. (2009) · Clinical Immunology · doi:10.1016/j.clim.2008.12.004 · Cited by 34
Self-citationIntrathecal chitotriosidase and the outcome of multiple sclerosis
Sotgiu, S., Barone, R., Arru, G., Fois, M. L., Pugliatti, M., Sanna, A., Rosati, G., & Musumeci, S. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070614 · Cited by 33
D’Aguanno, S., Barassi, A., Lupisella, S., et al. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.10.004 · Cited by 27
Improved resolution of human cerebrospinal fluid proteins on two-dimensional gels
Hammack, B. N., Owens, G. P., Burgoon, M. P., & Gilden, D. H. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms954oa · Cited by 21
Cited by
Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70274-5 · Cited by 507
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Self-citationYKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Self-citation
Metadata
- Authors
- Comabella, M., Fernández, M., Martin, R., Rivera-Vallvé, S., Borrás, E., Chiva, C., Julià, E., Rovira, A., Cantó, E., Alvarez-Cermeño, J. C., Villar, L. M., Tintoré, M., & Montalban, X.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-17
- Volume
- 133
- Issue
- 4
- Pages
- 1082-1093
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2151454941
- Cited by
- 300
- References
- 45
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.